Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals

(2016) Sandeep K. Agarwal   JOURNAL OF MANAGED CARE PHARMACY

One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population

(2015) Ronald Vender et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

(2014) Hideto Kameda et al.   Modern Rheumatology

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

(2014) Takao Koike et al.   Modern Rheumatology

Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials

(2014) Masaaki Mori et al.   Modern Rheumatology

Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan

(2014) Masaaki Mori et al.   Modern Rheumatology

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy

(2013) Esa Jämsen et al.   Acta Orthopaedica

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

(2013) Gerd Horneff et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis

(2013) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

(2013) Sang-Cheol Bae et al.   BMC MUSCULOSKELETAL DISORDERS

Diagnosing and treating psoriatic arthritis: an update

(2013) W.H. Boehncke et al.   BRITISH JOURNAL OF DERMATOLOGY

Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project

(2013) B. Nardone et al.   BRITISH JOURNAL OF DERMATOLOGY

High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register

(2013) Florenzo Iannone et al.   CLINICAL RHEUMATOLOGY

Certolizumab Pegol

(2013) Emma D. Deeks   DRUGS

Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy in the Latin American Region

(2013) Daniel A. Machado et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

(2013) Machaon Bonafede et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy

(2013) Mohammed Hammoudeh et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs

(2013) T. Koike et al.   JOURNAL OF RHEUMATOLOGY

OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis

(2013) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis

(2013) Mark G. Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

(2013) C. L. Morgan et al.   RHEUMATOLOGY

Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis

(2013) D van der Heijde et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review

(2013) Maurizio Pompili   WORLD JOURNAL OF GASTROENTEROLOGY

Improvement in Health-Related Quality of Life for Children With Juvenile Idiopathic Arthritis After Start of Treatment With Etanercept

(2013) Jens Klotsche et al.   ARTHRITIS CARE & RESEARCH

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years

(2013) Xenofon Baraliakos et al.   ARTHRITIS RESEARCH & THERAPY

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions

(2013) Jose Ramon Maneiro et al.   JAMA Internal Medicine

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis

(2013) Ronald Vender et al.   Applied Health Economics and Health Policy

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and

(2012) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Sanne A A van Dartel et al.   ANNALS OF THE RHEUMATIC DISEASES

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

(2012) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

(2012) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

(2012) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

(2012) Lluís Puig et al.   DERMATOLOGY

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

(2012) Robert Strohal et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Clinical Efficacy of Etanercept Versus Sulfasalazine in Ankylosing Spondylitis Subjects with Peripheral Joint Involvement

(2012) J. BRAUN et al.   JOURNAL OF RHEUMATOLOGY

Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

(2012) N. SOLARI et al.   JOURNAL OF RHEUMATOLOGY

Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study

(2012) M. Dougados et al.   RHEUMATOLOGY

Overview of safety of non-biologic and biologic DMARDs

(2012) E. M. Ruderman   RHEUMATOLOGY

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO

(2012) K. Minden et al.   RHEUMATOLOGY

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response

(2011) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)

(2011) M. Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial

(2011) Juergen Braun et al.   ARTHRITIS AND RHEUMATISM

Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial

(2011) Ho-Youn KIM et al.   International Journal of Rheumatic Diseases

Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis

(2011) Marieke H. Otten et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

(2011) H. KAMEDA et al.   JOURNAL OF RHEUMATOLOGY

Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

(2011) D. D. GLADMAN et al.   JOURNAL OF RHEUMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2011) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

(2011) David M. Pariser et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

(2011) R. Gniadecki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis

(2011) Takao Koike et al.   RHEUMATOLOGY INTERNATIONAL

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

(2011) Takao Koike et al.   RHEUMATOLOGY INTERNATIONAL

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis

(2010) Edward H. Giannini et al.   ARTHRITIS AND RHEUMATISM

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

(2010) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

(2010) M. H. OTTEN et al.   JOURNAL OF RHEUMATOLOGY

Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries

(2010) A. GIBOFSKY et al.   JOURNAL OF RHEUMATOLOGY

Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Intermittent etanercept therapy in pediatric patients with psoriasis

(2010) Elaine C. Siegfried et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term etanercept in pediatric patients with plaque psoriasis

(2010) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

(2010) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

(2010) JC Prinz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients

(2010) T. R. Southwood et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis

(2010) An D. Billiau et al.   RHEUMATOLOGY

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

(2010) V. Papsdorf et al.   RHEUMATOLOGY

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

(2010) W. G. Dixon et al.   ARTHRITIS CARE & RESEARCH

Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis

(2009) F H M Prince et al.   ANNALS OF THE RHEUMATIC DISEASES

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

(2009) J Kekow et al.   ANNALS OF THE RHEUMATIC DISEASES

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

(2009) J D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease control and health-related quality of life in juvenile idiopathic arthritis

(2009) Michael Seid et al.   ARTHRITIS AND RHEUMATISM

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

(2009) E. H. Giannini et al.   ARTHRITIS AND RHEUMATISM

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

(2009) J.-P. Ortonne et al.   BRITISH JOURNAL OF DERMATOLOGY

Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial

(2009) K. Gebauer et al.   BRITISH JOURNAL OF DERMATOLOGY

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

(2009) Kristian Reich et al.   DERMATOLOGY

Patients with Moderate Rheumatoid Arthritis (RA) Achieve Better Disease Activity States with Etanercept Treatment Than Patients with Severe RA

(2009) E. KEYSTONE et al.   JOURNAL OF RHEUMATOLOGY

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

(2009) E Daudén et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis

(2009) G. Horneff et al.   RHEUMATOLOGY

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

(2009) A. Anis et al.   RHEUMATOLOGY

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

(2009) Anna Rita Giardina et al.   RHEUMATOLOGY INTERNATIONAL

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

(2009) M. Halbig et al.   RHEUMATOLOGY INTERNATIONAL

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

(2008) T Bongartz et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

(2008) F H M Prince et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

(2008) G Horneff et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

(2008) Daniel J. Lovell et al.   ARTHRITIS AND RHEUMATISM

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

(2008) D. van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

(2008) Amy S. Paller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years

(2008) N. Tzaribachev et al.   RHEUMATOLOGY INTERNATIONAL

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial

(2007) P L C M van Riel et al.   ANNALS OF THE RHEUMATIC DISEASES

Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment

(2007) Joel M. Gelfand et al.   VALUE IN HEALTH